Treatments for recurrent penile cancer
Recurrent penile cancer means that the cancer has come back after it has been treated. The following are treatment options for recurrent penile cancer. The treatment for recurrent cancer depends on where the cancer comes back and what treatments were used before. Your healthcare team will suggest treatments based on your needs and work with you to develop a treatment plan.
You may be offered surgery for recurrent penile cancer. The types of surgery used are:
Partial or total penectomy is surgery that removes part or all of the penis.
Lymph node dissection may be used to remove lymph nodes that have cancer.
Radiation therapy @(Model.HeadingTag)>
You may be offered external beam radiation therapy or brachytherapy for recurrent penile cancer. Radiation therapy may be given:
- instead of surgery
- before surgery (neoadjuvant radiation therapy)
- after surgery (
Drug therapy @(Model.HeadingTag)>
You may be offered chemotherapy for recurrent penile cancer. Chemotherapy may be given:
- before surgery
- after surgery
- along with radiation therapy (called chemoradiation)
Clinical trials @(Model.HeadingTag)>
American Cancer Society. Penile Cancer. 2015: http://www.cancer.org/acs/groups/cid/documents/webcontent/003132-pdf.pdf.
American Society of Clinical Oncology. Penile Cancer. 2014: http://www.cancer.net/cancer-types/penile-cancer.
Brosman, SA. Medscape Reference: Penile Cancer. 2015: http://emedicine.medscape.com/article/446554-overview.
National Cancer Institute. Penile Cancer Treatment (PDQ®). 2016: http://www.cancer.gov/types/penile/patient/penile-treatment-pdq.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Penile Cancer (Version 2.2016). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
Penn Medicine. All about penile cancer. University of Pennsylvania; 2016: https://www.oncolink.org/cancers/penile-cancer/all-about-penile-cancer.
Richter S, Ruether JD, Wood L, Canil C, Moretto P, et al . Management of carcinoma of the penis: consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). Canadian Urological Association Journal. 2013.